Literature DB >> 25470010

Predicting the effectiveness of insulin pump therapy on glycemic control in clinical practice: a retrospective study of patients with type 1 diabetes from 10 outpatient diabetes clinics in Sweden over 5 years.

Mark Clements1, Viktorija Matuleviciene, Stig Attvall, Magnus Ekelund, Aldina Pivodic, Sofia Dahlqvist, Martin Fahlén, Börje Haraldsson, Marcus Lind.   

Abstract

BACKGROUND: Multicenter long-term studies of predictors for the effectiveness of continuous subcutaneous insulin infusion (CSII) in clinical practice are lacking. We hypothesized that there are substantially greater reductions in hemoglobin A1c (HbA1c) in patients with poor glycemic control and that other predictors may also exist. SUBJECTS AND METHODS: We used data from 10 outpatient diabetic clinics in Sweden and studied CSII treatment over 5 years. Patients with HbA1c values available ≤ 6 months before starting CSII and at 5 years were included (n = 272, 82% of CSII patients) along with 2,437 contemporaneous controls on multiple daily insulin injections (MDI). Baseline variables evaluated were age, sex, diabetes duration, insulin dose, body mass index (BMI), HbA1c at baseline, and outpatient clinical care unit.
RESULTS: At 5 years, significantly greater reductions in HbA1c by CSII compared with MDI were found for patients with higher baseline HbA1c (P = 0.032) and lower baseline BMI (P = 0.013). For baseline HbA1c levels of 7.0%, 8.0%, and 9.0% and a BMI of 25 kg/m(2), the reduction in HbA1c level by CSII was 0.08% (difference not significant), 0.16% (95% confidence interval, 0.03-0.29%), and 0.25% (95% confidence interval, 0.11-0.39%), respectively. Corresponding analyses for the change in HbA1c level from start to 1 and 2 years revealed a significant interaction of insulin pump therapy only with baseline HbA1c levels (P < 0.001 and P = 0.030, respectively). The interaction term between outpatient clinical care unit and CSII treatment was statistically significant for some care units, with some care units demonstrating a benefit from CSII and others demonstrating a detriment.
CONCLUSIONS: Patients with high HbA1c levels have a greater probability of improved HbA1c after initiating pump therapy, but effects remain relatively modest even for patients with poor control. Factors predicting successful insulin pump use need further study.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25470010     DOI: 10.1089/dia.2014.0139

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  4 in total

1.  Changes in HbA1c and Weight Following Transition to Continuous Subcutaneous Insulin Infusion Therapy in Adults With Type 1 Diabetes.

Authors:  Sanjeev N Mehta; Henrik Ullits Andersen; Martin J Abrahamson; Howard A Wolpert; Eva E Hommel; William McMullen; Martin Ridderstråle
Journal:  J Diabetes Sci Technol       Date:  2016-07-11

Review 2.  Health-system-based interventions to improve care in pediatric and adolescent type 1 diabetes.

Authors:  Sarah D Corathers; Pamela J Schoettker; Mark A Clements; Betsy A List; Deborah Mullen; Amy Ohmer; Avni Shah; Joyce Lee
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

3.  Quality of Life in Children With Diabetes Treated With Insulin Pump Compared With Multiple Daily Injections in Tertiary Care Center.

Authors:  Adnan Al Shaikh; Abdullah M Al Zahrani; Yousef H Qari; Abdulaziz A AbuAlnasr; Waseem K Alhawsawi; Khalid A Alshehri; Sahl A AlShaikh
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2020-09-28

4.  Three-variate trajectories of metabolic control, body mass index, and insulin dose: Heterogeneous response to initiation of pump therapy in youth with type 1 diabetes.

Authors:  Martin Tauschmann; Anke Schwandt; Nicole Prinz; Marianne Becker; Torben Biester; Melanie Hess; Martin Holder; Beate Karges; Andrea Näke; Oliver Kuss; Simone von Sengbusch; Reinhard W Holl
Journal:  Pediatr Diabetes       Date:  2022-02-04       Impact factor: 3.409

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.